Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 396 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Schedule C Clear all
Completed Not applicable Interventional Results available

Improving Diabetes Care Through Effective Personalized Patient Portal Interactions

NCT02953262
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
My HealtheVet Brochure, My HealtheVet Training Guide for Veterans Living with Diabetes, My HealtheVet Group Training, My HealtheVet Individual Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Bedford, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Not applicable Interventional

Testing the Effectiveness of Child and Parent-Targeted Health Promotion Interventions in Pediatric Stem Cell Transplantation

NCT00760227
View directory record Official record
Conditions
Bone Marrow, Stem Cell Transplant
Interventions
Massage Therapy, Humor Therapy, Relaxation Therapy
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
3
States / cities
Columbus, Ohio • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2011 · Synced Oct 21, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional

Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education

NCT06995924
View directory record Official record
Conditions
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Educational Intervention, Electronic Health Record Review, Internet-Based Intervention, Patient Navigation, Survey Administration
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Terminated Phase 4 Interventional Results available

Mindfulness Based Smoking Cessation Among Cancer Survivors

NCT04038255
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Nicoderm C-Q Transdermal Product, Orientation session, Craving-to-Quit app, Two brief follow-up phone calls, Group MT sessions, Brief advice on quitting smoking, Self-help smoking cessation materials
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Miami, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 1 Interventional Results available

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195
View directory record Official record
Conditions
Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
Interventions
PF-02341066, Rifampin, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
24
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 1:32 AM EDT
Active, not recruiting Phase 1 Interventional

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility and Effectiveness of a Telehealth-Delivered Inductive Reasoning Training Program for Older Adults

NCT05334186
View directory record Official record
Conditions
Reasoning Training
Interventions
Telehealth Reasoning Training
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
65 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

NCT02198794
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
44
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 21, 2026, 1:32 AM EDT
Recruiting Phase 3 Interventional

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297
View directory record Official record
Conditions
Neutropenia
Interventions
Mavorixafor, Placebo
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

IVIG (Gamunex-C) Treatment Study for POTS Subjects

NCT03919773
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
IVIG, Albumin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Not applicable Interventional

Diabetes Prevention for Mexican Americans

NCT03208010
View directory record Official record
Conditions
Prediabetic State, Overweight and Obesity
Interventions
Diabetes Prevention Intervention, Enhanced Usual Care
Behavioral · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
25 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Not applicable Interventional Results available

Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons

NCT02059408
View directory record Official record
Conditions
Hypertension
Interventions
Screen-Educate, Screen-Educate and Intensify Treatment
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
1,819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 21, 2026, 1:32 AM EDT
Completed No phase listed Observational Results available

Diaphragm Pacing in Individuals With Spinal Cord Injuries

NCT04179799
View directory record Official record
Conditions
Cervical Spinal Cord Injury
Interventions
Diaphragm Pacing
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704
View directory record Official record
Conditions
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
Interventions
ladiratuzumab vedotin, pembrolizumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
27
States / cities
Chandler, Arizona • Los Angeles, California • Santa Rosa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

NCT03441048
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Lintuzumab-Ac-225, Cladribine, Cytarabine, Mitoxantrone, G-CSF
Biological · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Milwuakee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 3 Interventional Results available

Long-Term PF-06651600 for the Treatment of Alopecia Areata

NCT04006457
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Not applicable Interventional

Improving Thinking in Everyday Life After Covid-19

NCT04644172
View directory record Official record
Conditions
Covid-19, Cognitive Impairment
Interventions
Speed of Processing Training, Instrumental Activities of Daily Living Shaping, Transfer Package from CI Therapy, Usual Care
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Active, not recruiting Phase 1 Interventional

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

NCT02291848
View directory record Official record
Conditions
Multiple Myeloma
Interventions
TAA-specific CTLs, TAA-specific CTLs- fixed dose
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

NCT04580121
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

NCT03978689
View directory record Official record
Conditions
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
Interventions
CUE-101, KEYTRUDA®, Pembrolizumab
Drug
Lead sponsor
Cue Biopharma
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nighttime Synchrony of Your Nutrition and Circadian Health

NCT07329283
View directory record Official record
Conditions
Sleep, Metabolism Changes, Circadian Rhythm, Lifestyle Factors, Sleep Hygiene, Sleep Hygiene, Inadequate, Sleep Deprivation, Insufficient Sleep, Circadian Misalignment, Circadian Dysregulation, Light Exposure
Interventions
Central Clock Misalignment, Peripheral Misalignment
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarkers for Event-driven PrEP Adherence

NCT04298697
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 1:32 AM EDT
Completed Phase 2 Interventional Results available

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00795002
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
alvocidib, mitoxantrone hydrochloride, cytarabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 21, 2026, 1:32 AM EDT